ANATOMIC STAGE III BREAST CANCER AJCC V8

This study tests two remote weight loss programs designed for Latina breast cancer survivors. The goal is to help participants lose weight and improve their long-term health. The study will enroll 640 women who have had breast cancer in the past 5 years and currently have no sign…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control

Last updated May 26, 2026 08:04 UTC

New drug cocktail targets Hard-to-Treat HER2 cancers

This early-stage trial tests the safety and best dose of combining two drugs—pidnarulex and trastuzumab deruxtecan—in people with advanced breast cancer or other solid tumors that have a protein called HER2. The study includes up to 36 adults whose cancer has spread, cannot be re…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 08:01 UTC

Can switching PARP inhibitors outsmart cancer? new trial aims to find out

This study is testing a drug called talazoparib in people with advanced solid tumors that have specific DNA repair gene mutations. The goal is to see if this PARP inhibitor can shrink tumors or slow their growth, even in patients who have already tried a similar drug. About 36 ad…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 07:59 UTC

New hope for tough breast cancer: early trial combines three drugs to fight tumors

This early-stage trial tests a new drug called ASTX727 alongside standard chemotherapy (paclitaxel) and immunotherapy (pembrolizumab) for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the com…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 07:58 UTC

5-Day radiation for breast cancer: a game changer?

This study tests a new, shorter radiation treatment for women with stage I-III breast cancer who have had a lumpectomy. Instead of weeks of daily radiation, patients receive 5 ultra-high-dose treatments to the whole breast and surgical area at once. The goal is to see if this app…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control

Last updated May 26, 2026 07:56 UTC

New triple-drug attack aims to shrink hard-to-treat breast cancer

This early-phase trial tests whether adding an experimental drug (ZEN003694) to standard chemotherapy and immunotherapy is safe for people with advanced triple-negative breast cancer that has spread. About 57 participants will receive the combination to find the best dose and che…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 07:55 UTC

New vaccine combo aims to supercharge immune attack on breast cancer

This study tests whether adding a vaccine called WOKVAC to standard chemotherapy and HER2-targeted therapy before surgery can boost the immune system to kill more breast cancer cells. About 25 adults with early-stage HER2-positive breast cancer will receive the vaccine alongside …

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control

Last updated May 26, 2026 07:53 UTC

Breast cancer survivors: could a common diabetes drug protect your heart?

This study looks at whether metformin, a common diabetes medicine, can help prevent or reverse insulin resistance (a step toward diabetes) in women who finished chemotherapy for early-stage breast cancer. About 200 women will either get metformin plus standard diet and exercise a…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE3 • Sponsor: City of Hope Medical Center • Aim: Disease control

Last updated May 26, 2026 07:53 UTC

Electric field therapy worn like a vest shows promise against tough cancers

This early-phase study tests a wearable device that creates low-intensity electric fields to disrupt cancer cell growth, combined with standard drugs (cabozantinib or nab-paclitaxel plus atezolizumab). About 43 adults with advanced solid tumors in the abdomen or chest that have s…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated May 26, 2026 07:52 UTC

Shorter radiation before or after breast surgery may cut side effects

This study compares giving a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) either before or after breast cancer surgery. The goal is to see which timing is safer and works better for different types of non-metastatic breast cancer. About 120 adults with …

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control

Last updated May 26, 2026 07:26 UTC

New drug cocktail targets Hard-to-Treat cancers in early trial

This early-phase study tests the safety and best dose of two drugs—ZEN003694 and abemaciclib—given together to people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or can't be removed by surgery. The goal is to see if the combination can shrin…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 26, 2026 07:25 UTC

Custom-Made cancer vaccine shows promise in advanced tumors

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control

Last updated May 22, 2026 14:04 UTC

Immunotherapy boost may stop High-Risk breast cancer return

This study tests whether adding an immunotherapy drug (durvalumab) to standard chemotherapy can prevent breast cancer from coming back in people with a high-risk form of hormone receptor-positive, HER2-negative breast cancer. About 3,680 adults with stage II or III breast cancer …

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated May 22, 2026 14:03 UTC

Promising combo targets Hard-to-Treat breast cancer

This study tests whether adding tamoxifen to a standard chemotherapy drug (liposomal doxorubicin) can shrink tumors in people with advanced triple-negative breast cancer that has spread or cannot be removed by surgery. About 30 adults who have already tried at least two other tre…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control

Last updated May 18, 2026 12:04 UTC

New study tests cheaper drug for ovarian suppression in breast cancer

This study compares two drugs, leuprolide and goserelin, to see how well they lower estrogen in premenopausal women with breast cancer. Both drugs stop the ovaries from making estrogen, which can fuel cancer growth. The trial will test if leuprolide works as well as goserelin. Ab…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control

Last updated May 12, 2026 13:42 UTC

BREAST CANCER BREAKTHROUGH: could less treatment be just as effective?

This study is for people with early-stage triple-negative breast cancer who had a complete response (no cancer left) after chemotherapy plus the immunotherapy drug pembrolizumab. The trial compares receiving more pembrolizumab versus simply being watched (observation) to see if t…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control

Last updated May 04, 2026 16:22 UTC

New hope for hard-to-treat breast cancer: drug combo targets resistance

Prevention Recruiting now

This study tests whether adding another drug (cediranib or AZD6738) to the PARP inhibitor olaparib can shrink tumors or slow cancer growth in people with advanced BRCA-mutated breast cancer that has stopped responding to PARP inhibitors. About 60 adults with HER2-negative, BRCA-p…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Apr 29, 2026 15:05 UTC

New ultrasound may predict chemo success early in breast cancer

Diagnosis Recruiting now

This study tests whether a special contrast-enhanced ultrasound can measure pressure inside breast tumors to predict how well chemotherapy is working. About 200 women with locally advanced breast cancer will get three ultrasounds before and during treatment. The goal is to see if…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2, PHASE3 • Sponsor: Kibo Nam • Aim: Diagnosis

Last updated May 20, 2026 11:53 UTC

New bypass procedure may prevent arm swelling in breast cancer patients

This study tests whether a preventive lymphovenous bypass—a rerouting of lymphatic fluid—can stop lymphedema (arm swelling) from developing after lymph node removal. About 252 adults with advanced breast cancer or melanoma will receive the bypass before their scheduled lymph node…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention

Last updated May 26, 2026 08:00 UTC

Can a Hair-Growing drug fix Chemo-Free hair loss?

This study tests whether minoxidil (a hair-growth drug) can reduce hair loss caused by hormone therapy in breast cancer patients. About 50 women with stages I-IV breast cancer who are on hormone therapy and have noticed hair thinning will take either a pill or apply a solution da…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: EARLY_PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief

Last updated May 26, 2026 08:03 UTC

Stress relief trial for aggressive breast cancer launches

This study tests whether a 10-week stress reduction program is practical and helpful for people with triple negative breast cancer. The program teaches relaxation, coping skills, and communication, and also connects participants with social services for needs like transportation …

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief

Last updated May 26, 2026 08:03 UTC

Potato power: could a simple starch stop cancer drug joint pain?

This study tests whether a dietary supplement called resistant potato starch can help prevent joint pain and stiffness caused by aromatase inhibitors, a common breast cancer treatment. About 20 people with early-stage breast cancer or at high risk for it will take the starch dail…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief

Last updated May 26, 2026 07:58 UTC

Brain food: could a special diet beat chemobrain?

This study looks at whether a healthy eating plan called the MIND diet can reduce memory and thinking problems (chemobrain) and other symptoms like fatigue and anxiety in women with stage II-III triple-negative breast cancer during chemotherapy. About 60 women will be randomly as…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief

Last updated May 26, 2026 07:58 UTC

Can better skin boost confidence in breast cancer survivors?

This study looks at how skin quality and self-esteem change in breast cancer survivors who are starting a type of hormone therapy called aromatase inhibitors. About 35 women with early-stage breast cancer will join. Researchers will use special imaging to track skin changes and s…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Sponsor: Mayo Clinic • Aim: Symptom relief

Last updated May 26, 2026 07:57 UTC

Gentler chemo for seniors: DOROTHY trial aims to cut side effects

This study looks at whether a lower dose of the chemotherapy drugs docetaxel and cyclophosphamide can effectively treat early-stage breast cancer in women aged 65 and older. Standard doses often cause harsh side effects in older patients. The goal is to find a dose that works wel…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief

Last updated May 26, 2026 07:57 UTC

Needles vs. pain: new study aims to keep black women on lifesaving breast cancer meds

This study tests whether in-person acupuncture or virtual acupressure can prevent the joint pain that often causes Black women to stop taking their breast cancer hormone therapy. About 150 Non-Hispanic Black postmenopausal women with early-stage breast cancer will be enrolled. Th…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: NA • Sponsor: Emory University • Aim: Symptom relief

Last updated May 22, 2026 13:54 UTC

Laser treatment offers hope for breast cancer survivors suffering from vaginal dryness

This study tests a vaginal laser treatment for breast cancer survivors who have vaginal dryness, often caused by cancer treatments like chemotherapy or hormone therapy. About 250 women who finished their main cancer treatment at least a year ago will receive either the laser or a…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief

Last updated May 18, 2026 11:59 UTC

New ultrasound marker could make breast cancer surgery more precise

This early-stage study tests a new type of marker that shows up better on ultrasound for people with breast cancer that has spread to lymph nodes. The marker is placed in the lymph node to help doctors find and remove the right node during surgery. The goal is to see if this mark…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Knowledge-focused

Last updated May 26, 2026 08:03 UTC

New tool aims to ease tough breast cancer surgery decisions

This study is testing a decision-making tool for women newly diagnosed with early-stage breast cancer. The tool helps them weigh the option of removing the healthy breast as a preventive measure. Researchers want to see if the tool is clear, balanced, and reduces confusion when m…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused

Last updated May 26, 2026 07:58 UTC

Gene test could predict breast cancer drug success

This study looks at how a specific gene change (HSD3B1) affects the way postmenopausal women with early-stage, hormone-sensitive breast cancer respond to the drug letrozole before surgery. Researchers will measure changes in tumor markers to see if the gene variant makes the drug…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE4 • Sponsor: University of Washington • Aim: Knowledge-focused

Last updated May 26, 2026 07:55 UTC

Genetic matchmaking for cancer: ComboMATCH trial aims to personalize therapy

This study screens people with advanced solid tumors to see if their cancer has specific genetic changes. Based on those results, they may be matched to a treatment trial that targets their tumor's unique genetics. The goal is to learn how well these targeted combinations work an…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused

Last updated May 26, 2026 07:52 UTC

Breast cancer and sleepless nights: new study investigates the link

This study looks at how sleep changes in women with early-stage breast cancer during treatment. Researchers will track sleep patterns and quality in 100 participants before, during, and after chemotherapy or radiation. The goal is to understand why sleep problems happen and how s…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused

Last updated May 26, 2026 07:26 UTC

Researchers track immune cells in HER2 breast cancer patients

This study looks at blood and tumor samples from 230 adults with HER2-positive breast cancer (stages I-IV) who are starting anti-HER2 drugs like trastuzumab. The goal is to learn how the immune system reacts to these treatments. No new therapy is being tested; instead, researcher…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Sponsor: Mayo Clinic • Aim: Knowledge-focused

Last updated May 22, 2026 13:53 UTC

Breast cancer survivors needed for biobank study

This study collects blood samples and health information from 1,300 women who have had stage I-III breast cancer and finished active treatment. The goal is to create a biorepository for future research into how individual factors affect long-term cancer outcomes. Participants wil…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Sponsor: University of Southern California • Aim: Knowledge-focused

Last updated May 18, 2026 12:08 UTC

Can a PET scan predict breast cancer drug success?

This study tests whether a special PET scan can predict if a drug combination (abemaciclib plus hormone therapy) will work for people with advanced hormone receptor-positive, HER2-negative breast cancer. About 60 participants will get the treatment and have imaging scans to see i…

Matched conditions: ANATOMIC STAGE III BREAST CANCER AJCC V8

Phase: PHASE2 • Sponsor: University of Washington • Aim: Knowledge-focused

Last updated May 18, 2026 12:08 UTC

Can your social life help you beat Cancer's aftermath?